Literature DB >> 7746978

A Bayesian group sequential design for a multiple arm randomized clinical trial.

G L Rosner1, D A Berry.   

Abstract

Group sequential designs for randomized clinical trials allow analyses of accruing data. Most group sequential designs in the literature concern the comparison of two treatments and maintain an overall prespecified type I error. As the number of treatments increases, however, so does the probability of falsely rejecting the null hypothesis. Bayesian statisticians concern themselves with the observed data and abide by the likelihood principle. As long as previous analyses do not change the likelihood, these analyses do not change Bayesian inference. In this paper, we discuss a group sequential design for a proposed randomized clinical trial comparing four treatment regimens. Bayesian ideas underlie the design and posterior probability calculations determine the criteria for stopping accrual to one or more of the treatments. We use computer simulation to estimate the frequentists properties of the design, information of interest to many of our collaborators. We show that relatively simple posterior probability calculations, along with simulations to calculate power under alternative hypotheses, can produce appealing designs for randomized clinical trials.

Mesh:

Substances:

Year:  1995        PMID: 7746978     DOI: 10.1002/sim.4780140405

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  3 in total

1.  Using short-term response information to facilitate adaptive randomization for survival clinical trials.

Authors:  Xuelin Huang; Jing Ning; Yisheng Li; Elihu Estey; Jean-Pierre Issa; Donald A Berry
Journal:  Stat Med       Date:  2009-05-30       Impact factor: 2.373

2.  Bayesian sequential meta-analysis design in evaluating cardiovascular risk in a new antidiabetic drug development program.

Authors:  Ming-Hui Chen; Joseph G Ibrahim; H Amy Xia; Thomas Liu; Violeta Hennessey
Journal:  Stat Med       Date:  2013-12-16       Impact factor: 2.373

3.  Do we need to adjust for interim analyses in a Bayesian adaptive trial design?

Authors:  Elizabeth G Ryan; Kristian Brock; Simon Gates; Daniel Slade
Journal:  BMC Med Res Methodol       Date:  2020-06-10       Impact factor: 4.615

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.